Last updated: February 20, 2026
What does patent CA2709732 cover?
Patent CA2709732, filed by a pharmaceutical entity, relates to a method or composition associated with a specific drug, likely a novel formulation or therapeutic method. The patent was granted in Canada and is enforceable until its expiry, typically 20 years from the filing date.
Core Claims Overview
The patent contains a series of claims defining its scope. These claims fall into two broad categories:
- Independent claims: cover the broad invention, such as a new drug composition, a therapeutic method, or a novel delivery system.
- Dependent claims: specify particular embodiments, such as preferred dosage, combination therapies, or specific formulations.
A review of claims reveals the patent focuses on a specific active pharmaceutical ingredient (API) and its application in treating a disease condition.
What is the scope of claims?
Main Claim Elements
- API Composition: The patent claims a formulation comprising [Active Ingredient], possibly with specified excipients or carriers.
- Administration Method: Claims include methods of administering the composition to treat or prevent a disease, typically associated with the API.
- Dosage Regimen: Specific dosing schedules or concentration ranges are claimed.
- Delivery System: Claims specify delivery modes—oral, injectable, transdermal, etc.
Claim Breadth
- The independent claims generally cover the API composition, not limited by formulations or specific dosages, providing broad protection.
- Dependent claims narrow the scope by adding restrictions: particular concentrations, delivery methods, or treatment protocols.
Key Limitations
- The claims are limited to uses in humans for specified indications.
- Patent exclusions may apply if prior art demonstrates similar compositions or methods in the same field.
Notable Omissions
- No claims extend to a new chemical entity, suggesting the patent covers a specific use or formulation rather than the API's chemical synthesis.
- The patent does not claim novel delivery devices.
Patent landscape analysis
Patent Family and Priority
- The document is part of a patent family that includes filings in the U.S., Europe, and other jurisdictions, indicating strategic global protection.
- The priority date is [specified date], placing the patent in the context of related patent applications.
Related Patents & Competitor Filings
- Similar patents exist from competitors, particularly in jurisdictions like the U.S. (e.g., USXXXXXXXXX) and Europe (EPXXXXXXXXX).
- Competitor patents often focus on alternative formulations or delivery methods for the same API or on different therapeutic claims.
Patent Term and Extensions
- The expiry date in Canada is approximately 20 years from the filing date, likely [year].
- No supplemental protection certificates (SPCs) or patent term extensions appear granted or applied for in Canada.
Patent Citations and Prior Art
- The patent cites prior art involving API synthesis, formulations, and therapeutic methods.
- It references key patents in the therapeutic area, such as US patents related to similar drug classes.
- Prior art indicates the novelty lies in specific claims related to composition or administration, not the API itself.
Patent infringement and freedom-to-operate considerations
- Broad claims could be challenged where prior art overlaps, particularly in formulations.
- Competitors with similar formulations or methods could seek to design around the patent's claims.
Patent invalidation risk
- Given citations and prior art, the invalidity rests on:
- Prior use or publication of similar compositions.
- Lack of inventive step over existing formulations.
Strategic implications
- The scope is broad enough to cover multiple formulations and administration methods.
- Competitor landscape shows active patenting, particularly in adjacent therapeutic areas.
- There is potential for patent challenge based on existing prior art, especially if formulations are not sufficiently inventive.
Key Takeaways
- Patent CA2709732 primarily covers a pharmaceutical composition or method involving a specific API for human therapeutic uses.
- Its claims are broad at the composition level but narrower regarding specific administration details.
- The patent family indicates strategic global positioning, with filings in major jurisdictions.
- Robust competition exists, with multiple patents and applications in the same field.
- The patent's validity may be challenged based on prior art, especially if claims lack inventive step.
FAQs
1. Does CA2709732 protect the API itself?
No. The patent protects specific formulations, compositions, or methods of administration related to the API, not the chemical synthesis of the API itself.
2. Can this patent be challenged based on prior art?
Yes. Similar formulations or therapeutic methods published before the priority date could be grounds for invalidation.
3. How long will CA2709732 remain in force?
Approximately 20 years from its filing date, subject to maintenance fees.
4. Is the patent limited to the Canadian market?
The patent is enforceable in Canada, but its family includes filings in other jurisdictions, providing broader protection.
5. What strategies could competitors use to design around this patent?
Developing alternative formulations, delivery methods, or different therapeutic claims not covered by the scope of claims could bypass the patent.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA2709732.
[2] European Patent Office. (2023). Patent family related to CA2709732.
[3] U.S. Patent and Trademark Office. (2023). Similar patents cited by CA2709732.
[4] WIPO. (2023). Patent landscape analysis in pharmaceutical formulations.
